Prodrugs: A Novel Approach of Drug Delivery

Rishabh Gaur

doi:doi:10.11648/j.ijpc.20241002.11

Research Article |

| Peer-Reviewed

Prodrugs: A Novel Approach of Drug Delivery

Rishabh Gaur^*

Published in International Journal of Pharmacy and Chemistry (Volume 10, Issue 2)

Received: 23 May 2024 Accepted: 15 June 2024 Published: 29 June 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

In the last one-decade numbers of review and research, articles have been published on prodrugs. This shows the interest of researchers in prodrugs because of the advantages offered by them over other drug delivery systems. Prodrug design is a method to focus many of the issues that trouble drug discovery and development, such as solidity, virulence, solubility, permeability, and drug targeting. Prodrug design is an effective method for targeting medications by altering their physiochemical, pharmacological, or pharmacokinetic properties. Prodrugs account for about 10% to 14% of all drugs sanctioned worldwide. Prodrugs can be created for a variety of administration methods, including transdermal, oral, intravenous, and more. However, the oral route of administration is the most popular and preferable approach; hence, oral prodrugs are highlighted in this article. Our main objectives are to explain the fundamental ideas behind the prodrug strategy, give a rundown of successfully registered oral prodrugs, and evaluate the therapeutic gains made in contrast to the parent drug. In this review article, we have made an attempt to incorporate all the basic details of prodrugs like Introductions, classification, applications of prodrug design in diverse fields of drug development, and basic functional categories that are amenable to prodrug design are all covered in this article. Using electronic databases such Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane, a literature search was conducted to locate information.

Published in	International Journal of Pharmacy and Chemistry (Volume 10, Issue 2)
DOI	10.11648/j.ijpc.20241002.11
Page(s)	18-24
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Prodrugs, Development, Classification, Application, Functional Categories, Virulence

References

[1]	Sun, X.; Vilar, S.; Tatonetti, N. P. High-throughput methods for combinatorial drug discovery. Sci. Transl. Med., 2013, 5, 205-201.
[2]	Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46, 3–26.
[3]	Gupta, D.; Bhatia, D.; Dave, V.; Sutariya, V.; Varghese. Gupta. S. Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations., 2018, 23, 1719.
[4]	Knittel, J. J.; Zavod, R. M. Drug design and relationship of functional groups to pharmacologic activity. In: Lemke, T.; Williams, D. A.; Roche, V. F.; Zito, S. W. editors. Foye’s Principles of Medicinal Chemistry. 7th ed. Wolters Kluwer Lippincott Williams and Wilkins; London, UK: 2013. p. 51.
[5]	Beig, A.; Fine-Shamir, N.; Porat, D.; Lindley, D.; Miller, J. M.; Dahan, A. Concomitant solubility-permeability increase: Vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide. Eur. J. Pharm. Biopharm. Off. J. Arb. Fur. Pharm. Verfahr. EV., 2017, 121, 97–103.
[6]	Beig, A.; Miller, J. M.; Lindley, D.; Carr, R. A.; Zocharski, P.; Agbaria, R.; Dahan, A. Head-to-Head comparison of different solubility-enabling formulations of etoposide and their consequent solubility-permeability interplay. J. Pharm. Sci., 2015, 104, 2941–2947.
[7]	Dahan, A.; Beig, A.; Lindley, D.; Miller, J. M. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one. Adv, Drug, Deliv, Rev., 2016, 101, 99–107.
[8]	Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem., 2004, 47, 2393–2404.
[9]	Stella, V. J. Prodrugs as therapeutics. Expert, Opin, Ther, Pat., 2004, 14, 277–280.
[10]	Rautio, J.; Meanwell, N. A.; Di, L.; Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug. Discov., 2018, 17, 559–587.
[11]	Tripathi, K. D. Essentials of medical pharmacology, 6th edition, 2009, 23.
[12]	Khade, M. M.; Salunkhe, A. M.; Doijad, R. C.; Patil, S. J. A Prodrug Design: Synthesis and Biological Screening of Cox II Inhibitor. J. curr. Pharma. res., 2013, 3(2), 784.
[13]	Dahan, A.; Khamis, M.; Agbaria, R.; Karaman, R. Targeted prodrugs in oral drug delivery: The modern molecular biopharmaceutical approach. Expert. Opin. Drug. Deliv., 2012, 9, 1001–1013.
[14]	Dahan, A.; Zimmermann, E. M.; Ben-Shabat, S. Modern prodrug design for targeted oral drug delivery. Molecules. 2014, 19, 16489–16505.
[15]	Markovic, M.; Ben-Shabat, S.; Dahan, A. Lipidic prodrugs for drug delivery: Opportunities and challenges. In: Kamal Shah, D. N. C.; Chauhan, N. S.; Mishra, P. editors. Recent Advancement in Prodrugs. Taylor & Francis Group; Abingdon-on-Thames, UK: 2020.
[16]	Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility. Adv. Drug. Deliv. Rev., 2007, 59, 677–694.
[17]	Stella, V. J. Prodrug approaches to enhancing the oral delivery of poorly permeable drugs. In: Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; Oliyai, R.; Maag, H.; Tilley, J. W. editors. Prodrugs: Challenges and Rewards Part 1. Springer New York; New York, NY, USA: 2007. pp. 37–82.
[18]	Markovic, M.; Ben-Shabat, S.; Keinan, S.; Aponick, A.; Zimmermann, E. M.; Dahan, A. Lipidic prodrug approach for improved oral drug delivery and therapy. Med. Res. Rev., 2019, 39, 579–607.
[19]	Linderoth, L.; Fristrup, P.; Hansen, M.; Melander, F.; Madsen, R.; Andresen, T. L.; Peters, G. H. Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid. J. Am. Chem. Soc., 2009, 131, 12193–12200.
[20]	Markovic, M.; Ben-Shabat, S.; Dahan, A. Computational simulations to guide enzyme-mediated prodrug activation. Int. J. Mol. Sci., 2020, 21, 3621.
[21]	Markovic, M.; Ben-Shabat, S.; Keinan, S.; Aponick, A.; Zimmermann, E. M.; Dahan, A. Molecular modeling-guided design of phospholipid-based prodrugs. Int. J. Mol. Sci., 2019, 20, 2210.
[22]	Stella, V. J. Prodrugs Challenges and Rewards. Springer; New York, NY, USA: 2007. A Case for prodrugs; p. 1464.
[23]	Han, H. K.; Amidon, G. L. Targeted prodrug design to optimize drug delivery. AAPS. Pharm. Sci., 2000, 2, 1–11.
[24]	Hu, L.; The prodrug approach to better targeting; Meeting Report of Prodrugs: Effective Solutions for Solubility, Permeability, and Targeting Challenges; Philadelphia, PA, USA. 28-29 June 2004; [accessed on 10 October 2023]. Available online: www.currentdrugdiscovery.com
[25]	Liederer, B. M.; Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci., 2006, 95, 1177–1195.
[26]	Smith and Williams, Introduction to the Principles of Drug Design and Action, 4th Ed, Taylor and Francis Group, USA: 216-230.
[27]	Yang, Y. h.; Aloysius, H.; Inoyama, D.; Chen, Y.; Hu, Lq. Enzyme-mediated hydrolytic activation of prodrugs. Acta. Pharm. Sin. B., 2011, 1, 143–159.
[28]	Sun, J.; Dahan, A.; Amidon, G. L. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: A double-targeted prodrug approach. J. Med. Chem., 2010, 53, 624–632.
[29]	Sun, J.; Dahan, A.; Walls, Z. F.; Lai, L.; Lee, K. D.; Amidon, G. L. Specificity of a prodrug-activating enzyme hVACVase: The leaving group effect. Mol. Pharm., 2010, 7, 2362–2368.
[30]	Sun, J.; Miller, J. M.; Beig, A.; Rozen, L.; Amidon, G. L.; Dahan, A. Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality. Expert. Opin. Drug. Metab. Toxicol., 2011, 7, 313–323.
[31]	US Food and Drug Administration, Emergency Use Authorization (EUA) for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. [(accessed on 11 October 2023)]; Available online: https://www.fda.gov/media/137564/download
[32]	Lo, M. K.; Albariño, C. G.; Perry, J. K.; Chang, S.; Tchesnokov, E. P.; Guerrero, L.; Chakrabarti, A.; Shrivastava-Ranjan, P.; Chatterjee, P.; McMullan, L. K. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proc. Natl. Acad. Sci., USA. 2020.
[33]	Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL); ClinicalTrials. gov Identifier: NCT04315324. [(accessed on 11 October 2023)].
[34]	This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. [(accessed on 11 October 2023)]; ClinicalTrials. gov Identifier: NCT03592264.
[35]	Evans, K.; Duan, J.; Pritchard, T.; Jones, C. D.; McDermott, L.; Gu, Z.; Toscan, C. E.; El-Zein, N.; Mayoh, C.; Erickson, S. W. OBI-3424, a Novel AKR1C3-Activated prodrug, exhibits potent efficacy against preclinical models of T-ALL. Clin. Cancer. Res: Off. J. Am. Assoc. Cancer. Res., 2019, 25, 4493–4503.
[36]	Hayden, F. G.; Sugaya, N.; Hirotsu, N.; Lee, N.; de Jong, M. D.; Hurt, A. C.; Ishida, T.; Sekino, H.; Yamada, K.; Portsmouth, S. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. New. Engl. J. Med., 2018, 379, 913–923.
[37]	Mullard, A. 2018 FDA drug approvals. Nat. Reviews. Drug. Discov., 2019, 18, 85–89.
[38]	Simonneau, G.; Torbicki, A.; Hoeper, M. M.; Delcroix, M.; Karlócai, K.; Galiè, N.; Degano, B.; Bonderman, D.; Kurzyna, M.; Efficace, M. Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur. Respir. J., 2012, 40, 874.
[39]	Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995; 39(12): 2759–2764.
[40]	Kim, I.; Chu, X. Y.; Kim, S.; Provoda, C. J.; Lee, K. D.; Amidon, G. L. Identification of a human valacyclovirase: Biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem. 2003, 278, 25348–25356.
[41]	Cundy, K. C.; Branch, R.; Chernov-Rogan, T.; Dias, T.; Estrada, T.; Hold, K.; Koller, K.; Liu, X.; Mann, A.; Panuwat, M. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther., 2004, 311, 315–323.
[42]	Markovic, M.; Ben-Shabat, S.; Dahan, A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics., 2020, 12(11), 1031.
[43]	Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer (NuTide:121); ClinicalTrials. gov Identifier: NCT04163900. [(accessed on 11 October 2023)].
[44]	Arora, M.; Bogenberger, J. M.; Abdelrahman, A.; Leiting, J. L.; Chen, X.; Egan, J. B.; Kasimsetty, A.; Lenkiewicz, E.; Malasi, S.; Uson, P. L. S. Evaluation of NUC-1031: A first-in-class ProTide in biliary tract cancer. Cancer. Chemother. Pharmacol., 2020.
[45]	Alanazi, A. S.; James, E.; Mehellou, Y. The protide prodrug technology: Where next? A. C. S. Med. Chem. Lett., 2019, 10, 2–5.
[46]	Dahan, A.; Ben-Shabat, S.; Cohen, N.; Keinan, S.; Kurnikov, I.; Aponick, A.; Zimmermann, E. M. Phospholipid-Based prodrugs for drug targeting in inflammatory bowel disease: Computational optimization and in-vitro correlation. Curr. Top. Med. Chem. 2016, 16, 2543–2548.
[47]	Markovic M, Ben-Shabat S, Dahan A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics. 2020 Oct 29; 12(11): 1031.
[48]	Gupta D., Bhatia D., Dave V., Sutariya V., Varghese Gupta S. Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations. Molecules. 2018; 23: 1719.
[49]	Jung, D.; Dorr, A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999, 39(8), 800–804.
[50]	Xie, A. Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine. 2020, 56.
[51]	Zhang, T. Y.; Synergistic effects of co-administration of suicide gene expressing mesenchymal stem cells and prodrug-encapsulated liposome on aggressive lung melanoma metastases in mice. J. Control. Release., 2015, 209, 260-271.
[52]	Gennaro, R.; Alfanso, W. Remington: The science and practice of pharmacy, Lippincott Williams & Wilkins. 2003, 20(1), 913-914.
[53]	Daniel, H.; Kottra, G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 2004, 447(5), 610–618.
[54]	Wilska, J. B.; Wojcieszak, J.; Olejniczak, A. B. Prodrugs: a challenge for the drug development. Pharmacol. Rep., 2013, 65(1), 1–14.
[55]	Patil, S. J.; Shirote, P. J. Prodrug approach: an effective solution to overcome side-effects. Int. J. Med. Pharm. Sci., 2011, 1(7), 1-13.
[56]	Ohlanet. Mutual prodrugs- a swot analysis. IJPSR., 2011, 2(4), 719-729.
[57]	Longqin, H. U. Prodrug: Effective solutions for solubility, permeability and challenges Drugs. 2004; 7(8).
[58]	Shargel, A. B.; Andrew, B. C. Applied in pharmaceutics & Pharmacokinetics, 4th Ed. McGraw-Hill Medical Publishing Division, US. 47-66, 129-154.

Cite This Article

Plain Text BibTeX RIS

APA Style

Gaur, R. (2024). Prodrugs: A Novel Approach of Drug Delivery. International Journal of Pharmacy and Chemistry, 10(2), 18-24. https://doi.org/10.11648/j.ijpc.20241002.11

Copy | Download

ACS Style

Gaur, R. Prodrugs: A Novel Approach of Drug Delivery. Int. J. Pharm. Chem. 2024, 10(2), 18-24. doi: 10.11648/j.ijpc.20241002.11

Copy | Download

AMA Style

Gaur R. Prodrugs: A Novel Approach of Drug Delivery. Int J Pharm Chem. 2024;10(2):18-24. doi: 10.11648/j.ijpc.20241002.11

Copy | Download

@article{10.11648/j.ijpc.20241002.11,
  author = {Rishabh Gaur},
  title = {Prodrugs: A Novel Approach of Drug Delivery
},
  journal = {International Journal of Pharmacy and Chemistry},
  volume = {10},
  number = {2},
  pages = {18-24},
  doi = {10.11648/j.ijpc.20241002.11},
  url = {https://doi.org/10.11648/j.ijpc.20241002.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijpc.20241002.11},
  abstract = {In the last one-decade numbers of review and research, articles have been published on prodrugs. This shows the interest of researchers in prodrugs because of the advantages offered by them over other drug delivery systems. Prodrug design is a method to focus many of the issues that trouble drug discovery and development, such as solidity, virulence, solubility, permeability, and drug targeting. Prodrug design is an effective method for targeting medications by altering their physiochemical, pharmacological, or pharmacokinetic properties. Prodrugs account for about 10% to 14% of all drugs sanctioned worldwide. Prodrugs can be created for a variety of administration methods, including transdermal, oral, intravenous, and more. However, the oral route of administration is the most popular and preferable approach; hence, oral prodrugs are highlighted in this article. Our main objectives are to explain the fundamental ideas behind the prodrug strategy, give a rundown of successfully registered oral prodrugs, and evaluate the therapeutic gains made in contrast to the parent drug. In this review article, we have made an attempt to incorporate all the basic details of prodrugs like Introductions, classification, applications of prodrug design in diverse fields of drug development, and basic functional categories that are amenable to prodrug design are all covered in this article. Using electronic databases such Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane, a literature search was conducted to locate information.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Prodrugs: A Novel Approach of Drug Delivery

AU  - Rishabh Gaur
Y1  - 2024/06/29
PY  - 2024
N1  - https://doi.org/10.11648/j.ijpc.20241002.11
DO  - 10.11648/j.ijpc.20241002.11
T2  - International Journal of Pharmacy and Chemistry
JF  - International Journal of Pharmacy and Chemistry
JO  - International Journal of Pharmacy and Chemistry
SP  - 18
EP  - 24
PB  - Science Publishing Group
SN  - 2575-5749
UR  - https://doi.org/10.11648/j.ijpc.20241002.11
AB  - In the last one-decade numbers of review and research, articles have been published on prodrugs. This shows the interest of researchers in prodrugs because of the advantages offered by them over other drug delivery systems. Prodrug design is a method to focus many of the issues that trouble drug discovery and development, such as solidity, virulence, solubility, permeability, and drug targeting. Prodrug design is an effective method for targeting medications by altering their physiochemical, pharmacological, or pharmacokinetic properties. Prodrugs account for about 10% to 14% of all drugs sanctioned worldwide. Prodrugs can be created for a variety of administration methods, including transdermal, oral, intravenous, and more. However, the oral route of administration is the most popular and preferable approach; hence, oral prodrugs are highlighted in this article. Our main objectives are to explain the fundamental ideas behind the prodrug strategy, give a rundown of successfully registered oral prodrugs, and evaluate the therapeutic gains made in contrast to the parent drug. In this review article, we have made an attempt to incorporate all the basic details of prodrugs like Introductions, classification, applications of prodrug design in diverse fields of drug development, and basic functional categories that are amenable to prodrug design are all covered in this article. Using electronic databases such Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane, a literature search was conducted to locate information.

VL  - 10
IS  - 2
ER  -

Copy | Download

Author Information

Rishabh Gaur

Department of Pharmacology, Roorkee College of Pharmacy, Roorkee, India

Contact Email

http://orcid.org/0000-0003-4707-6371

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Gaur, R. (2024). Prodrugs: A Novel Approach of Drug Delivery. International Journal of Pharmacy and Chemistry, 10(2), 18-24. https://doi.org/10.11648/j.ijpc.20241002.11

Copy | Download

ACS Style

Gaur, R. Prodrugs: A Novel Approach of Drug Delivery. Int. J. Pharm. Chem. 2024, 10(2), 18-24. doi: 10.11648/j.ijpc.20241002.11

Copy | Download

AMA Style

Gaur R. Prodrugs: A Novel Approach of Drug Delivery. Int J Pharm Chem. 2024;10(2):18-24. doi: 10.11648/j.ijpc.20241002.11

Copy | Download

@article{10.11648/j.ijpc.20241002.11,
  author = {Rishabh Gaur},
  title = {Prodrugs: A Novel Approach of Drug Delivery
},
  journal = {International Journal of Pharmacy and Chemistry},
  volume = {10},
  number = {2},
  pages = {18-24},
  doi = {10.11648/j.ijpc.20241002.11},
  url = {https://doi.org/10.11648/j.ijpc.20241002.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijpc.20241002.11},
  abstract = {In the last one-decade numbers of review and research, articles have been published on prodrugs. This shows the interest of researchers in prodrugs because of the advantages offered by them over other drug delivery systems. Prodrug design is a method to focus many of the issues that trouble drug discovery and development, such as solidity, virulence, solubility, permeability, and drug targeting. Prodrug design is an effective method for targeting medications by altering their physiochemical, pharmacological, or pharmacokinetic properties. Prodrugs account for about 10% to 14% of all drugs sanctioned worldwide. Prodrugs can be created for a variety of administration methods, including transdermal, oral, intravenous, and more. However, the oral route of administration is the most popular and preferable approach; hence, oral prodrugs are highlighted in this article. Our main objectives are to explain the fundamental ideas behind the prodrug strategy, give a rundown of successfully registered oral prodrugs, and evaluate the therapeutic gains made in contrast to the parent drug. In this review article, we have made an attempt to incorporate all the basic details of prodrugs like Introductions, classification, applications of prodrug design in diverse fields of drug development, and basic functional categories that are amenable to prodrug design are all covered in this article. Using electronic databases such Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane, a literature search was conducted to locate information.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Prodrugs: A Novel Approach of Drug Delivery

AU  - Rishabh Gaur
Y1  - 2024/06/29
PY  - 2024
N1  - https://doi.org/10.11648/j.ijpc.20241002.11
DO  - 10.11648/j.ijpc.20241002.11
T2  - International Journal of Pharmacy and Chemistry
JF  - International Journal of Pharmacy and Chemistry
JO  - International Journal of Pharmacy and Chemistry
SP  - 18
EP  - 24
PB  - Science Publishing Group
SN  - 2575-5749
UR  - https://doi.org/10.11648/j.ijpc.20241002.11
AB  - In the last one-decade numbers of review and research, articles have been published on prodrugs. This shows the interest of researchers in prodrugs because of the advantages offered by them over other drug delivery systems. Prodrug design is a method to focus many of the issues that trouble drug discovery and development, such as solidity, virulence, solubility, permeability, and drug targeting. Prodrug design is an effective method for targeting medications by altering their physiochemical, pharmacological, or pharmacokinetic properties. Prodrugs account for about 10% to 14% of all drugs sanctioned worldwide. Prodrugs can be created for a variety of administration methods, including transdermal, oral, intravenous, and more. However, the oral route of administration is the most popular and preferable approach; hence, oral prodrugs are highlighted in this article. Our main objectives are to explain the fundamental ideas behind the prodrug strategy, give a rundown of successfully registered oral prodrugs, and evaluate the therapeutic gains made in contrast to the parent drug. In this review article, we have made an attempt to incorporate all the basic details of prodrugs like Introductions, classification, applications of prodrug design in diverse fields of drug development, and basic functional categories that are amenable to prodrug design are all covered in this article. Using electronic databases such Web of Science, Google Scholar, PubMed, Sci Finder, Reaxys, and Cochrane, a literature search was conducted to locate information.

VL  - 10
IS  - 2
ER  -

Copy | Download